The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Trial of celecoxib in amyotrophic lateral sclerosis
Abstract
Objective: To determine whether chronic treatment with celecoxib, a cyclooxygenase‐2 inhibitor that has been shown to be beneficial in preclinical testing, is safe and effective in amyotrophic lateral sclerosis (ALS). Methods: A double‐blind, placebo‐controlled, clinical trial was conducted. Three hundred research subjects with ALS were randomized (2:1) to receive celecoxib (800mg/day) or placebo for 12 months. The primary outcome measure was the rate of change in upper extremity motor function measured by the maximum voluntary isometric contraction strength. Secondary end points included safety, survival, change in cerebrospinal fluid prostaglandin E 2 levels, and changes in the rate of decline of leg and grip strength, vital capacity, ALS Functional Rating Scale‐Revised, and motor unit number estimates. Results: Celecoxib did not slow the decline in muscle strength, vital capacity, motor unit number estimates, ALS Functional Rating Scale‐Revised, or affect survival. Celecoxib was well tolerated and was not associated with an increased frequency of adverse events. Prostaglandin E 2 levels in cerebrospinal fluid were not elevated at baseline and did not decline with treatment. Interpretation: At the dosage studied, celecoxib did not have a beneficial effect on research subjects with ALS, and it was safe. A biological effect of celecoxib was not demonstrated in the cerebrospinal fluid. Further studies of celecoxib at a dosage of 800mg/day in ALS are not warranted. Ann Neurol 2006;60:22–31
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rothstein, J. D., Dykes-Hoberg, M., Pardo, C. A., Bristol, L. A., Jin, L., Kuncl, R. W., Kanai, Y., Hediger, M. A., Wang, Y., Schielke, J. P., et al. (1996) · Neuron · doi:10.1016/s0896-6273(00)80086-0 · Cited by 2,534
Self-citationDose-ranging study of riluzole in amyotrophic lateral sclerosis
Amyotrophic Lateral Sclerosis/Riluzole Study Group II, Lacomblez, L., Bensimon, G., Meininger, V, Leigh, P. N., & Guillet, P. (1996) · The Lancet · doi:10.1016/s0140-6736(96)91680-3 · Cited by 1,301
Prostaglandins stimulate calcium-dependent glutamate release in astrocytes
Bezzi, P., Carmignoto, G., Pasti, L., Vesce, S., Rossi, D., Rizzini, B. L., Pozzan, T., & Volterra, A. (1998) · Nature · doi:10.1038/34651 · Cited by 1,143
Functional Role of Caspase-1 and Caspase-3 in an ALS Transgenic Mouse Model
Li, M., Ona, V. O., Guégan, C., Chen, M., Jackson-Lewis, V., Andrews, L. J., Olszewski, A. J., Stieg, P. E., Lee, J.-P., Przedborski, S., et al. (2000) · Science · doi:10.1126/science.288.5464.335 · Cited by 716
Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis
Klivenyi, P., Ferrante, R. J., Matthews, R. T., Bogdanov, M. B., Klein, A. M., Andreassen, O. A., Mueller, G., Wermer, M., Kaddurah-Daouk, R., & Beal, M. F. (1999) · Nature Medicine · doi:10.1038/6568 · Cited by 682
Abnormal excitatory amino acid metabolism in amyotrophic lateral sclerosis
Rothstein, J. D., Tsai, G., Kuncl, R. W., Clawson, L., Cornblath, D. R., Drachman, D. B., Pestronk, A., Stauch, B. L., & Coyle, J. T. (1990) · Annals of Neurology · doi:10.1002/ana.410280106 · Cited by 636
Self-citationCloning Two Isoforms of Rat Cyclooxygenase: Differential Regulation of Their Expression
Feng, L., Sun, W. Q., Xia, Y. Y., Tang, W. W., Chanmugam, P., Soyoola, E., Wilson, C. B., & Hwang, D. (1993) · Archives of Biochemistry and Biophysics · doi:10.1006/abbi.1993.1601 · Cited by 452
(1996) · Archives of Neurology · doi:10.1001/archneur.1996.00550020045014 · Cited by 415
Neuroprotective Function of the PGE2EP2 Receptor in Cerebral Ischemia
McCullough, L., Wu, L., Haughey, N., Liang, X., Hand, T., Wang, Q., Breyer, R. M., & Andreasson, K. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.4485-03.2004 · Cited by 361
Self-citationIncreased oxidative damage to DNA in ALS patients
Bogdanov, M., Brown, R. H., Matson, W., Smart, R., Hayden, D., O’Donnell, H., Flint Beal, M., & Cudkowicz, M. (2000) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(00)00349-x · Cited by 334
Self-citation
Cited by
Mechanisms underlying inflammation in neurodegeneration
Glass, C. K., Saijo, K., Winner, B., Marchetto, M. C., & Gage, F. H. (2010) · Cell · doi:10.1016/j.cell.2010.02.016 · Cited by 3,580
ALS: A Disease of Motor Neurons and Their Nonneuronal Neighbors
Boillée, S., Vande Velde, C., & Cleveland, D. W. (2006) · Neuron · doi:10.1016/j.neuron.2006.09.018 · Cited by 1,429
Microglia polarization from M1 to M2 in neurodegenerative diseases
Guo, S., Wang, H., & Yin, Y. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.815347 · Cited by 920
Neuroinflammation in amyotrophic lateral sclerosis: role of glial activation in motor neuron disease
Philips, T., & Robberecht, W. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70015-1 · Cited by 646
Henkel, J. S., Engelhardt, J. I., Siklós, L., Simpson, E. P., Kim, S. H., Pan, T., Goodman, J. C., Siddique, T., Beers, D. R., & Appel, S. H. (2004) · Annals of Neurology · doi:10.1002/ana.10805 · Cited by 559
Mead, R. J., Shan, N., Reiser, H. J., Marshall, F., & Shaw, P. J. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00612-2 · Cited by 505
Modulating inflammatory monocytes with a unique microRNA gene signature ameliorates murine ALS
Butovsky, O., Siddiqui, S., Gabriely, G., Lanser, A. J., Dake, B., Murugaiyan, G., Doykan, C. E., Wu, P. M., Gali, R. R., Iyer, L. K., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci62636 · Cited by 481
Self-citationDi Giorgio, F. P., Boulting, G. L., Bobrowicz, S., & Eggan, K. C. (2008) · Cell Stem Cell · doi:10.1016/j.stem.2008.09.017 · Cited by 485
Inflammatory processes in amyotrophic lateral sclerosis
McGeer, P. L., & McGeer, E. G. (2002) · Muscle & Nerve · doi:10.1002/mus.10191 · Cited by 470
ALS clinical trials review: 20 years of failure. Are we any closer to registering a new treatment?
Petrov, D., Mansfield, C., Moussy, A., & Hermine, O. (2017) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00068 · Cited by 451
Choi, S.-H., Aid, S., & Bosetti, F. (2009) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2009.01.002 · Cited by 402
Liu, J., & Wang, F. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01005 · Cited by 376
Lost in translation: Treatment trials in the SOD1 mouse and in human ALS
Benatar, M. (2007) · Neurobiology of Disease · doi:10.1016/j.nbd.2006.12.015 · Cited by 350
Schwartz, M., & Baruch, K. (2014) · The EMBO Journal · doi:10.1002/embj.201386609 · Cited by 349
Rodent Models of Amyotrophic Lateral Sclerosis
Philips, T., & Rothstein, J. D. (2015) · Current Protocols in Pharmacology · doi:10.1002/0471141755.ph0567s69 · Cited by 294
Self-citationPaganoni, S., Deng, J., Jaffa, M., Cudkowicz, M. E., & Wills, A. (2011) · Muscle & Nerve · doi:10.1002/mus.22114 · Cited by 293
Self-citationElectrical impedance myography: Background, current state, and future directions
Rutkove, S. B. (2009) · Muscle & Nerve · doi:10.1002/mus.21362 · Cited by 292
Mitsumoto, H., Brooks, B. R., & Silani, V. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70129-2 · Cited by 289
The PRO-ACT database: Design, initial analyses, and predictive features
Atassi, N., Berry, J., Shui, A., Zach, N., Sherman, A., Sinani, E., Walker, J., Katsovskiy, I., Schoenfeld, D., Cudkowicz, M., et al. (2014) · Neurology · doi:10.1212/wnl.0000000000000951 · Cited by 285
Self-citationProtective and Toxic Neuroinflammation in Amyotrophic Lateral Sclerosis
Hooten, K. G., Beers, D. R., Zhao, W., & Appel, S. H. (2015) · Neurotherapeutics · doi:10.1007/s13311-014-0329-3 · Cited by 275
Microglia and neuroprotection: From in vitro studies to therapeutic applications
Polazzi, E., & Monti, B. (2010) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2010.06.009 · Cited by 262
Systemic inflammatory cells fight off neurodegenerative disease
Schwartz, M., & Shechter, R. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.71 · Cited by 240
Aggarwal, S. P., Zinman, L., Simpson, E., McKinley, J., Jackson, K. E., Pinto, H., Kaufman, P., Conwit, R. A., Schoenfeld, D., Shefner, J., et al. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70068-5 · Cited by 195
Self-citationAmyotrophic Lateral Sclerosis: From Current Developments in the Laboratory to Clinical Implications
Cozzolino, M., Ferri, A., & Teresa Carrì, M. (2008) · Antioxidants & Redox Signaling · doi:10.1089/ars.2007.1760 · Cited by 156
Béland, L.-C., Markovinovic, A., Jakovac, H., De Marchi, F., Bilic, E., Mazzini, L., Kriz, J., & Munitic, I. (2020) · Brain Communications · doi:10.1093/braincomms/fcaa124 · Cited by 125
Molecular targets of non-steroidal anti-inflammatory drugs in neurodegenerative diseases
Lleo, A., Galea, E., & Sastre, M. (2007) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-007-6516-1 · Cited by 93
Miller, R. G., Moore, D. H., Forshew, D. A., Katz, J. S., Barohn, R. J., Valan, M., Bromberg, M. B., Goslin, K. L., Graves, M. C., McCluskey, L. F., et al. (2011) · Neurology · doi:10.1212/wnl.0b013e31822dc7a5 · Cited by 70
Amyotrophic lateral sclerosis pathogenesis: a journey through the secretory pathway
Nassif, M., Matus, S., Castillo, K., & Hetz, C. (2010) · Antioxidants & Redox Signaling · doi:10.1089/ars.2009.2991 · Cited by 60
Bowerman, M., Vincent, T., Scamps, F., Perrin, F. E., Camu, W., & Raoul, C. (2013) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2013.00214 · Cited by 46
Metadata
- Authors
- Cudkowicz, M. E., Shefner, J. M., Schoenfeld, D. A., Zhang, H., Andreasson, K. I., Rothstein, J. D., Drachman, D. B., & Northeast ALS Consortium
- Venue
- Annals of Neurology
- Publisher
- Wiley
- Published
- 2006-06-26
- Volume
- 60
- Issue
- 1
- Pages
- 22-31
- ISSN
- 0364-5134 (ISSN-L)
- 1531-8249
- OpenAlex
- W2097367691
- Cited by
- 301
- References
- 36
- FWCI
- 13.17
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.